{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:4791"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:4791","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Modelling and preventing the development of chronic communicating hydrocephalus","abstract":"In post-haemorrhagic communicating hydrocephalus, CSF drainage is obstructed by subarachnoid fibrosis in which the fibrogenic cytokine transforming growth factor-β1 (TGF-β1) has been aetiologically implicated. Here, the hypothesis that the TGF-β antagonist Decorin has therapeutic potential for (1) reducing fibrosis and the development of hydrocephalus and (2) degrading fibrosis and resolving hydrocephalus, was tested using a rat model of juvenile communicating hydrocephalus. In the acute study, hydrocephalus was induced by a basal cistern injection of kaolin in 3-week-old rats, immediately followed by continuous intraventricular infusion of either human recombinant Decorin or PBS. In the chronic study, hydrocephalus was allowed to develop for 7 days before starting the treatment of Decorin or PBS. Ventricular expansion was measured by magnetic resonance imaging. Inflammation, fibrosis, Decorin, TGF-β/Smad2/3 activation and hydrocephalic brain pathology were evaluated by immunohistochemistry and basic histology. In the acute study continuous Decorin infusion prevented the development of hydrocephalus by blocking TGF-β- induced subarachnoid fibrosis and protected against hydrocephalic brain damage. In the chronic study Decorin had no impact on hydrocephalus, TGF-β1 levels or subarachnoid fibrosis, however the efficiency of Decorin infusion was in disrepute. The results suggest that Decorin is a potential clinical therapeutic for the prevention of juvenile post-haemorrhagic communicating hydrocephalus.","abstract_html":"In post-haemorrhagic communicating hydrocephalus, CSF drainage is obstructed by subarachnoid fibrosis in which the fibrogenic cytokine transforming growth factor-β1 (TGF-β1) has been aetiologically implicated. Here, the hypothesis that the TGF-β antagonist Decorin has therapeutic potential for (1) reducing fibrosis and the development of hydrocephalus and (2) degrading fibrosis and resolving hydrocephalus, was tested using a rat model of juvenile communicating hydrocephalus. In the acute study, hydrocephalus was induced by a basal cistern injection of kaolin in 3-week-old rats, immediately followed by continuous intraventricular infusion of either human recombinant Decorin or PBS. In the chronic study, hydrocephalus was allowed to develop for 7 days before starting the treatment of Decorin or PBS. Ventricular expansion was measured by magnetic resonance imaging. Inflammation, fibrosis, Decorin, TGF-β/Smad2/3 activation and hydrocephalic brain pathology were evaluated by immunohistochemistry and basic histology. In the acute study continuous Decorin infusion prevented the development of hydrocephalus by blocking TGF-β- induced subarachnoid fibrosis and protected against hydrocephalic brain damage. In the chronic study Decorin had no impact on hydrocephalus, TGF-β1 levels or subarachnoid fibrosis, however the efficiency of Decorin infusion was in disrepute. The results suggest that Decorin is a potential clinical therapeutic for the prevention of juvenile post-haemorrhagic communicating hydrocephalus.","abstract_has_math":false,"creators":["Botfield, Hannah Florence"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-07","date_published":"2014-07","updated_at":"2026-11-19T09:27:51Z","subjects":["R Medicine (General)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/4791/2/Botfield14PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A4791","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["bbsrc"]},{"key":"dc:creator","label":"Author","values":["Botfield, Hannah Florence"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2014-07"]},{"key":"dc:date.issued","label":"Date","values":["2014-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","School of Clinical and Experimental Medicine"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/4791/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["R Medicine (General)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/4791/2/Botfield14PhD.pdf","http://etheses.bham.ac.uk//id/eprint/4791/1/Decl_IS_Botfield14PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["In post-haemorrhagic communicating hydrocephalus, CSF drainage is obstructed by subarachnoid fibrosis in which the fibrogenic cytokine transforming growth factor-β1 (TGF-β1) has been aetiologically implicated. Here, the hypothesis that the TGF-β antagonist Decorin has therapeutic potential for (1) reducing fibrosis and the development of hydrocephalus and (2) degrading fibrosis and resolving hydrocephalus, was tested using a rat model of juvenile communicating hydrocephalus. In the acute study, hydrocephalus was induced by a basal cistern injection of kaolin in 3-week-old rats, immediately followed by continuous intraventricular infusion of either human recombinant Decorin or PBS. In the chronic study, hydrocephalus was allowed to develop for 7 days before starting the treatment of Decorin or PBS. Ventricular expansion was measured by magnetic resonance imaging. Inflammation, fibrosis, Decorin, TGF-β/Smad2/3 activation and hydrocephalic brain pathology were evaluated by immunohistochemistry and basic histology. In the acute study continuous Decorin infusion prevented the development of hydrocephalus by blocking TGF-β- induced subarachnoid fibrosis and protected against hydrocephalic brain damage. In the chronic study Decorin had no impact on hydrocephalus, TGF-β1 levels or subarachnoid fibrosis, however the efficiency of Decorin infusion was in disrepute. The results suggest that Decorin is a potential clinical therapeutic for the prevention of juvenile post-haemorrhagic communicating hydrocephalus."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["Modelling and preventing the development of chronic communicating hydrocephalus"]}]}],"canonical_facts":{"dc:contributor.sponsor":["bbsrc"],"dc:creator":["Botfield, Hannah Florence"],"dc:date":["2014-07"],"dc:date.issued":["2014-07"],"dc:description.abstract":["In post-haemorrhagic communicating hydrocephalus, CSF drainage is obstructed by subarachnoid fibrosis in which the fibrogenic cytokine transforming growth factor-β1 (TGF-β1) has been aetiologically implicated. Here, the hypothesis that the TGF-β antagonist Decorin has therapeutic potential for (1) reducing fibrosis and the development of hydrocephalus and (2) degrading fibrosis and resolving hydrocephalus, was tested using a rat model of juvenile communicating hydrocephalus. In the acute study, hydrocephalus was induced by a basal cistern injection of kaolin in 3-week-old rats, immediately followed by continuous intraventricular infusion of either human recombinant Decorin or PBS. In the chronic study, hydrocephalus was allowed to develop for 7 days before starting the treatment of Decorin or PBS. Ventricular expansion was measured by magnetic resonance imaging. Inflammation, fibrosis, Decorin, TGF-β/Smad2/3 activation and hydrocephalic brain pathology were evaluated by immunohistochemistry and basic histology. In the acute study continuous Decorin infusion prevented the development of hydrocephalus by blocking TGF-β- induced subarachnoid fibrosis and protected against hydrocephalic brain damage. In the chronic study Decorin had no impact on hydrocephalus, TGF-β1 levels or subarachnoid fibrosis, however the efficiency of Decorin infusion was in disrepute. The results suggest that Decorin is a potential clinical therapeutic for the prevention of juvenile post-haemorrhagic communicating hydrocephalus."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/4791/2/Botfield14PhD.pdf","http://etheses.bham.ac.uk//id/eprint/4791/1/Decl_IS_Botfield14PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","School of Clinical and Experimental Medicine"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/4791/"],"dc:subject":["R Medicine (General)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["Modelling and preventing the development of chronic communicating hydrocephalus"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:27:51Z"}